For 31 years, she tried everything.
Medication after medication. Therapy after therapy. Electroconvulsive treatment. Hospitalisation. The full arsenal of psychiatric medicine — deployed, adjusted, combined, and redeployed — against a depression so deep and so persistent that it had become the defining fact of her life.
None of it worked. Not really. Not lastingly.
Then came the implant.
The woman, a 44-year-old whose case has been documented in medical literature as a landmark breakthrough in psychiatric neuroscience, has now experienced something she had not felt in over three decades: genuine joy. Not the temporary lifting of symptoms. Not a blunting of pain. **Actual happiness.** The feeling of looking forward to things. Of life being worth living.
The treatment that achieved this is called **deep brain stimulation (DBS)** — and this case represents one of the most personalised applications of the technology ever attempted.
**What Is Deep Brain Stimulation?**
DBS involves implanting a small device in the brain that delivers precisely calibrated electrical pulses to targeted neural circuits. It is already FDA-approved for Parkinson's disease, essential tremor, and OCD, and has been used experimentally for treatment-resistant depression for over a decade — with mixed results.
The 'mixed' part is important. Early DBS trials for depression used standardised targets — the same brain region, the same stimulation parameters, for every patient. Some responded dramatically. Others showed little improvement. The variance was frustrating and not fully understood.
What makes this case different is **personalisation**.
**A System Designed for One Person's Brain**
The medical team began by extensively mapping this particular patient's neural activity — identifying the precise brain circuits associated with her depressive episodes and, crucially, the biomarkers that predicted when those episodes were intensifying.
They then programmed the DBS device not just to stimulate a target region, but to respond in real time to her brain's own signals. This 'closed-loop' approach — where the implant senses neural patterns and adjusts stimulation accordingly — represents a major advance over earlier, constant-stimulation devices.
The results were rapid. Within weeks of activation, the patient reported mood improvements unlike anything she had experienced in three decades. By subsequent follow-up assessments, she was described by clinicians as functioning at a level that would not have been imaginable before the intervention.
'What we witnessed was not merely symptom relief,' one of the researchers involved noted. 'It was a restoration of the capacity for joy.'
**Why This Matters**
Treatment-resistant depression — defined as depression that fails to respond adequately to at least two different antidepressant treatments — affects an estimated **30% of people with depression globally**. That translates to hundreds of millions of people worldwide for whom the standard toolkit of medication and therapy is insufficient.
For many, the consequences are devastating: inability to work, social isolation, chronic suffering, and elevated suicide risk. The need for better options is urgent and real.
Personalised DBS is not yet a scalable solution — the technology remains expensive, requires neurosurgery, and demands specialised expertise. But this case demonstrates the proof of concept that has been missing: that by precisely targeting an individual's specific neural architecture, and adapting stimulation to real-time brain feedback, treatment-resistant depression can be meaningfully overcome.
**The Broader Horizon**
The TRANSCEND clinical trial — sponsored by Abbott and enrolling patients across 25 US sites — is currently evaluating DBS for treatment-resistant depression in a rigorous randomised controlled trial. Mount Sinai performed the first implant under this protocol in 2025; results are anticipated within the next two years.
Researchers have also identified theta brainwave signatures that predict DBS response before surgery, potentially allowing clinicians to select patients most likely to benefit.
Meanwhile, for one woman who spent 31 years in darkness, something extraordinary has already happened.
She can feel joy. 💙
Sources: Victorian Workplace Commission (Australia) · BBRF Foundation · Healio Neurology · Abbott TRANSCEND Trial